A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 5179-5186

  Lee, Su Jin ^a   Lee, Jeeyun ^a   Sohn, Insuk ^b   Mao, Mao ^c   Kai, Wang ^c   Park, Cheol Keun ^a   Lim, Ho Yeong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^c PFIZER INC   (United States)

Author keywords

c MET; Copy number variation; Hepatocellular carcinoma; Immunohistochemistry; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; C MET INHIBITOR; MESSENGER RNA; SCATTER FACTOR RECEPTOR; TIVANTINIB; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL FEATURE; COPY NUMBER VARIATION; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE C MET; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TUMOR INVASION; TUMOR VOLUME;

C-MET; COPY NUMBER VARIATION; HEPATOCELLULAR CARCINOMA; IMMUNOHISTOCHEMISTRY; PROGNOSIS;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DNA COPY NUMBER VARIATIONS; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891370054     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236, 2011.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M and Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430, 2001.
4. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
5. Llovet JM, Schwartz M and Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25: 181-200, 2005.
6. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M and Sassa T: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25: 87-92, 1997.
7. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, Takao T, Tamesa T, Tangoku A, Tabuchi H, Hamada K, Nakayama H, Ishitsuka H, Miyamoto T, Hirabayashi A, Uchimura S and Hamamoto Y: Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361: 923-929, 2003.
8. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S and Makuuchi M: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38: 200-207, 2003.
9. Inagaki Y, Tang W, Zhang L, Du G, Xu W and Kokudo N: Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis. Biosci Trends 4: 56-60, 2010.
10. Song P, Tang W, Tamura S, Hasegawa K, Sugawara Y, Dong J and Kokudo N: The management of hepatocellular carcinoma in Asia: A guideline combining quantitative and qualitative evaluation. Biosci Trends 4: 283-287, 2010.
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
12. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
13. Rosario M and Birchmeier W: How to make tubes: Signaling by the Met receptor tyrosine kinase. Trends Cell Biol 13: 328-335, 2003.
14. Zhang YW and Vande Woude GF: HGF/SF-METsignaling in the control of branching morphogenesis and invasion. J Cell Biochem 88: 408-417, 2003.
15. Trusolino L, Bertotti A and Comoglio PM: MET signalling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834-848, 2010.
16. Nakopoulou L, Gakiopoulou H, Keramopoulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J and Davaris PS: c-MET tyrosine kinase receptor expression is associated with abnormal β-catenin expression and favourable prognostic factors ininvasive breast carcinoma. Histopathology 36: 313-325, 2000.
17. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925, 2003.
18. Kiss A, Wang NJ, Xie JP and Thorgeirsson SS: Analysis of transforming growth factor (TGF)-α/epidermal growth factorreceptor, hepatocyte growth factor/c-MET,TGF-β receptor typeII, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 3: 1059-1066, 1997.
19. Ljubimova JY, Petrovic LM, Wilson SE, Geller SA and Demetriou AA: Expression of HGF, its receptor c-MET, c-MYC, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 45: 79-87, 1997.
20. Okano J, Shiota G and Kawasaki H: Expression of hepatocyte growth factor (HGF) and HGF receptor (c-MET) proteins in liver diseases: An immunohistochemical study. Liver 19: 151-159, 1999.
21. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y and Porta C: Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase II study. Lancet Oncol 14:55-63, 2013.
22. Edmondson HA SP: Primary carcinoma of the liver: A study of 100 cases among 48900 necropsies. Cancer 7: 462-503, 1954.
23. Japan LCSGo: Liver Cancer STudy Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Second English Edition. Kanehara p. 38, 2003.
24. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM and Golub TR: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004, 2008.
25. Kim SH, Ahn S and Park CK: SMAD3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy. Hepatobiliary Pancreat Dis Int 11: 51-59, 2012.
26. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193, 2003.
27. Comoglio PM, Giordano S and Trusolino L: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7: 504-516, 2008.
28. Ichimura E, Maeshima A, Nakajima T and Nakamura T: Expression of c-MET/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 87: 1063-1069, 1996.
29. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P and Charpin C: Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-MET and with proteomic basal-like phenotype. Hum Pathol 38: 830-841, 2007.
30. Takanami I, Tanana F, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T and Kodaira S: Hepatocyte growth factor and c-MET/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 53: 392-397, 1996.
31. Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL and Rimm DL: Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97: 1841-1848, 2003.
32. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y, Culliford ATt, D'Alessio M, Barany F and Paty PB: c-MET gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 265: 258-269, 2008.
33. Suzuki K, Hayashi N, Yamada Y, Yoshihara H, Miyamoto Y, Ito Y, Ito T, Katayama K, Sasaki Y, Ito A and et al.: Expression of the c-MET protooncogene in human hepatocellular carcinoma. Hepatology 20: 1231-1236, 1994.
34. D'Errico A, Fiorentino M, Ponzetto A, Daikuhara Y, Tsubouchi H, Brechot C, Scoazec JY and Grigioni WF: Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: Its specific receptor c-MET does. Hepatology 24: 60-64, 1996.
35. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, Bai DS, Li JC, Liu KD and Fan J: Role of overexpression of CD151 and/or c-MET in predicting prognosis of hepatocellular carcinoma. Hepatology 49: 491-503, 2009.
36. Osada S, Kanematsu M, Imai H and Goshima S: Clinical significance of serum HGF and c-MET expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 55: 544-549, 2008.
37. Ueki T, Fujimoto J, Suzuki T, Yamamoto H and Okamoto E: Expression of hepatocyte growth factor and its receptor c-METproto-oncogene in hepatocellular carcinoma. Hepatology 25:862-866, 1997.
38. Wang ZL, Liang P, Dong BW, Yu XL and Yu de J: Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: A retrospective study. J Gastrointest Surg 12: 327-337, 2008.
39. Kondo S, Ojima H, Tsuda H, Hashimoto J, Morizane C, Ikeda M, Ueno H, Tamura K, Shimada K, Kanai Y and Okusaka T: Clinical impact of c-MET expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol, 2012.
40. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A and Varella-Garcia M: Increased MET gene copy number negatively affects survival of surgically resected non-small cell lung cancer patients. J Clin Oncol 27: 1667-1674, 2009.
41. Go H, Jeon YK, Park HJ, Sung SW, Seo JW and Chung DH: High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 5: 305-313, 2010.
42. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, Bang YJ and Kim WH: MET in gastric carcinomas: Comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107: 325-333, 2012.
43. Park S, Choi YL, Sung CO, An J, Seo J, Ahn MJ, Ahn JS, Park K, Shin YK, Erkin OC, Song K, Kim J, Shim YM and Han J: High MET copy number and MET overexpression: Poor outcome in non-small cell lung cancer patients. Histol Histopathol 27: 197-207, 2012.
44. You H, Ding W, Dang H, Jiang Y and Rountree CB: c-MET represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54: 879-889, 2011.
45. Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, Carrier M, Huntsman D and Aparicio S: Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): Pathologist assessment compared to quantitative image analysis. BMC Cancer 9: 165, 2009.